Abbonarsi

Development and validation of a model for predicting 18-month mortality in type 2 myocardial infarction - 09/10/21

Doi : 10.1016/j.ajem.2021.04.060 
Truong H. Hoang, MD, PhD a, , Victor V. Maiskov, MD, PhD a, b, Imad A. Merai, MD, PhD a, b, Zhanna D. Kobalava, MD, DMedSc a
a Department of Internal Diseases with the Course of Cardiology and Functional Diagnostics named after V.S. Moiseev, Institute of Medicine, RUDN University, Moscow, Russia 
b Vinogradov City Clinical Hospital, Moscow, Russia 

Corresponding author at: Department of Internal Diseases with the Course of Cardiology and Functional Diagnostics named after V.S. Moiseev, Institute of Medicine, RUDN University, 117198, Miklukho-Maklaya Street, 6, Moscow, Russia.Department of Internal Diseases with the Course of Cardiology and Functional Diagnostics named after V.S. MoiseevInstitute of MedicineRUDN University117198, Miklukho-Maklaya Street, 6MoscowRussia

Abstract

Background

Despite the poor prognosis in patients with type 2 myocardial infarction (MI), no prospective data on risk stratification exists. The aim of this study was to develop and validate a model for prediction of 18-month mortality of among patients with type 2 MI (T2MI) and compare its performance with GRACE and TARRACO scores.

Methods

The prospective observational study included 712 consecutive patients diagnosed with MI undergoing coronary angiography <24 h between January 2017 and December 2018. Diagnosis of T2MI was adjusted according to Third universal definition. A prognostic model was developed by using Bayesian approach and logistic regression analysis with identifying predictors for mortality. The model was validated by bootstrap validation. Comparison performance between scores using Delong test.

Results

T2MI was identified in 174 (24.4%) patients. The median age of patients was 69 years, 52% were female. The mortality rate was 20.1% at 18 months. Prior MI, presence of ST elevation, hemoglobin level at admission, Charlson comorbidity index and were independently associated with 18-month mortality. The model to predict 18-month mortality showed excellent discrimination (optimism corrected c-statistic = 0.822) and calibration (corrected slope = 0.893). GRACE and TARRACO scores had moderate discrimination [c-statistic = 0.748 (95% CI 0.652–0.843) and 0.741, 95% CI 0.669–0.805), respectively] and inferior compared with model (p = 0.043 and 0.037, respectively).

Conclusions

The risk of mortality among T2MI patients could be accurately predicted by using common clinical characteristics and laboratory tests. Further studies are required with external validation of nomogram prior to clinical implementation.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

Modest performance of GRACE (AUC = 0.748) and TARRACO (AUC = 0.741) scores for 18-month mortality in type 2 MI.
Developed 18-month mortality model in type 2 MI included 4 factors: prior MI, ST elevation, hemoglobin level, comorbidity.
Model discrimination (AUC = 0.840, after bootstrapping corrected AUC= 0.822) and calibration (corrected slope = 0.893).
Model’s performance was surpassed GRACE (p = 0.043) and TARRACO (p = 0.037) scores for 18-month mortality in type 2 MI.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Type 2 myocardial infarction, Prognostic model, Mortality


Mappa


© 2021  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 48

P. 224-230 - ottobre 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Criticality index conducted in pediatric emergency department triage
  • Theodore W. Heyming, Chloe Knudsen-Robbins, William Feaster, Louis Ehwerhemuepha
| Articolo seguente Articolo seguente
  • The impact of emergency department observation units on a health system
  • Michael Perry, Nicole Franks, Stephen R. Pitts, Tim P. Moran, Anwar Osborne, Dane Peterson, Michael A. Ross

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.